Franco Vigile is an entrepreneur with over a decade of experience founding, building, and leading innovative companies across the life sciences and healthcare sectors. He is the Founder and Chief Executive Officer of N-Zyme Biomedical, where he is leading the development of first-in-class therapies for reflux disease through the strategic repurposing of approved pharmaceuticals.

Previously, Franco founded HaluGen, a pioneering genetics-based health screening platform, and GENNCO Holdings, a Canadian boutique advisory firm focused on strategic growth and corporate development. Throughout his career, he has successfully identified emerging opportunities, assembled high-performing teams, raised capital, and guided organizations through critical stages of growth.

Franco is passionate about advancing innovative healthcare solutions with the potential to improve patient outcomes while creating long-term value for shareholders.